Platform or Procedure: How a Surgical Robotics Company Used Market Research and Strategy Advisory to Resolve Its Most Consequential Product Strategy Decision

Executive Snapshot

Client

Surgical Robotics Systems Developer, United States & Western Europe

Situation/Challenge

The client had developed a capable general-purpose surgical robotics platform and faced a fundamental strategic fork: continue investing in broad platform versatility, or concentrate near-term development on two or three procedure categories where competitors were not yet entrenched. Leadership had been unable to reach consensus, with each side reinforced by different customer conversations rather than a structured market view.

Objective

Commission an independent global surgical robotics market research report establishing procedure-category-level competitive density and hospital purchasing criteria, then engage strategy advisory to resolve the investment question with an evidence-based roadmap.

Constancy Researchers Solution

Market Research Reports combined with Strategy & Growth Advisory — a Global Surgical Robots Market Report covering procedure-category competitive density, hospital capital equipment purchasing criteria, and reimbursement dynamics, followed by a strategy advisory engagement delivering a resolved product investment roadmap.

Impact

Market research confirmed that hospital purchasing committees were increasingly evaluating systems on procedure-specific clinical evidence rather than platform breadth, and identified two procedure categories where competitive density remained low despite strong underlying demand growth. Strategy advisory translated this into a concentrated, two-category investment recommendation.

Client Outcome

The board approved a strategy concentrating near-term clinical and regulatory investment in the two identified procedure categories while maintaining the existing platform's broader capability as a longer-term asset. The first procedure-specific clinical evidence programme launched within four months.

The Situation / Challenge

Surgical robotics occupies a distinctive position in medical capital equipment, where the purchasing decision is shaped by hospital capital committees, surgical chiefs, and the clinical evidence base supporting specific procedures. A platform performing capably across many procedures offers commercial breadth, but purchasing committees increasingly evaluate systems against depth of evidence in the procedures their surgeons actually perform.

The client had built a general-purpose platform with genuine capability across several specialties, but leadership was divided on where to direct the next phase of investment. The engineering team argued for continued versatility, citing hospital systems that valued one platform across departments. The clinical and commercial team argued for concentrated investment in two or three procedures where deeper evidence could create real differentiation.

Both sets of customer conversations were real, but neither side had the structured, market-wide evidence needed to determine which purchasing logic actually predominated, and the disagreement had begun slowing concrete investment decisions.

Key Challenges

  • No structured, procedure-category-level view of competitive density across the market, leaving the platform-versus-procedure debate without an objective foundation
  • No systematic research into how hospital capital committees actually weighted platform breadth against procedure-specific clinical evidence in purchasing decisions
  • Conflicting customer conversation evidence cited by different internal teams, with no way to determine which was more representative of the broader market
  • No competitive mapping identifying which procedure categories had entrenched, well-evidenced robotic competitors versus which remained genuinely open to entry
  • A leadership disagreement delaying clinical trial design and regulatory submission planning
  • Board expectation that the investment question be resolved with independent market evidence rather than continued internal advocacy from either team

In surgical robotics, the platform-versus-procedure-specific question is rarely about which approach is correct in the abstract — it is about where a concentrated clinical evidence investment can create differentiation a broader platform cannot.

Constancy Researchers Solution

Constancy Researchers approached the engagement recognising that the disagreement reflected two genuinely different hospital purchasing behaviours that needed measuring at the market level rather than argued through individual customer anecdotes.

Global Surgical Robots Market Sizing & Procedure Category Analysis
  • Delivered a market research report sizing the global surgical robotics market by procedure category, geography, and hospital system type, with five-year forecasts distinguishing established categories from emerging ones.
  • Identified that procedure categories with two or more established robotic competitors showed meaningfully slower new-entrant success, directly informing where concentrated investment was likely to succeed.
Hospital Purchasing Committee Decision Criteria Research
  • Researched the actual weighting hospital capital committees applied to platform breadth versus procedure-specific evidence, segmented by system size and academic versus community status.
  • Found that larger academic systems weighted procedure-specific evidence more heavily than platform breadth, while smaller community systems valued a single multi-department platform — a segmentation neither internal team had considered.
Competitive Density & White Space Mapping by Procedure Category
  • Mapped competitive density across all major procedure categories where robotic systems were in use or development, identifying which had entrenched incumbents and which remained genuinely accessible.
  • Identified two procedure categories combining strong demand growth, an absence of entrenched competitors with strong evidence, and alignment with the client’s existing platform.
Reimbursement & Regulatory Pathway Research
  • Researched reimbursement and regulatory pathway complexity for the two identified categories, assessing realistic timelines for generating the clinical evidence base needed.
  • Confirmed that both categories had reimbursement pathways already established for robotic-assisted procedures, removing a major source of internal uncertainty.
Resolved Investment Strategy & Commercial Roadmap
  • Synthesised findings into a resolved investment strategy, concentrating clinical and regulatory investment in the two identified categories while preserving the platform’s broader capability as a long-term asset.
  • Delivered a board-ready roadmap covering clinical trial design, regulatory submission sequencing, and a commercial plan differentiated by hospital system segment.

The engagement resolved a disagreement argued from incomplete and conflicting anecdotal evidence, replacing it with a segmented, market-wide understanding of purchasing behaviour.

Impact

  • Market research confirmed procedure categories with established robotic competitors showed meaningfully slower new-entrant success
  • Hospital purchasing research revealed a segmentation by hospital system size that neither internal team had previously considered
  • Competitive mapping identified two procedure categories combining strong demand growth with limited entrenched robotic competition
  • Reimbursement research confirmed established pathways for both identified categories, removing a significant source of internal uncertainty
  • The resolved investment strategy ended a leadership disagreement that had been delaying clinical trial design and regulatory planning
  • The board approved concentrated investment in the two identified procedure categories within weeks of strategy delivery
  • The first procedure-specific clinical evidence programme launched within four months of the engagement’s conclusion
  • The existing platform’s broader capability was preserved as a longer-term asset rather than abandoned, satisfying both sides of the original debate

Client Outcome

Strategic Resolution

A prolonged leadership disagreement over platform versus procedure-specific investment was resolved with market-wide evidence rather than continued anecdotal advocacy.

Investment Concentration

Clinical and regulatory investment was concentrated in two procedure categories combining strong demand growth with limited entrenched competition.

Segmentation Insight

A hospital system size segmentation explained why internal teams had been citing genuinely different but equally valid customer evidence.

Clinical Programme Launch

The first procedure-specific clinical evidence programme launched within four months, ending a period of delayed decision-making.

Reimbursement Confidence

Established reimbursement pathways for both target procedure categories removed a significant source of board uncertainty.

Platform Preservation

The existing platform's broader capability was retained as a long-term asset, avoiding the false choice the original internal debate had implied.

Commercial Differentiation

Concentrated investment in genuinely accessible procedure categories positioned the company to build clinical evidence depth competitors had not yet established.

Leadership Alignment

Engineering, clinical, and commercial leadership reached shared strategic direction for the first time, grounded in market evidence rather than competing internal narratives.

Market Positioning

The client was repositioned as a strategically focused surgical robotics company investing where evidence showed genuine competitive opportunity existed.

Case Studies

Learn how our success stories power data-driven growth across industries

Speak with an Analyst

    Download TOC